Related Experiment Video
Updated: Aug 11, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Tetronic 701-a novel hypocholesterolaemic agent
Atherosclerosis
|May 1, 1976
Summary
Tetronic 701 and 702 show hypocholesterolemic activity by reducing cholesterol levels in animal models. Derivatives of Tetronic 701 also demonstrated cholesterol-lowering effects with reduced growth depression.
Area of Science:
- Biochemistry
- Pharmacology
Background:
- Cholesterol management is crucial for cardiovascular health.
- Polymeric surface-active agents offer potential therapeutic avenues.
Purpose of the Study:
- To investigate the hypocholesterolemic activity of the Tetronic series of polymeric surface-active agents.
- To identify specific Tetronic compounds with cholesterol-lowering properties and understand their mechanisms.
Main Methods:
- Screening of Tetronic series agents in rats on a hypercholesterolemic diet.
- In vivo studies in rats, chicks, and rabbits to assess cholesterol reduction.
- In vitro experiments evaluating cholesterol precipitation from micelles.
- Synthesis and testing of Tetronic 701 derivatives.
Main Results:
- Tetronics 701 and 702 exhibited significant hypocholesterolemic activity in animal models.
- Tetronic 701 reduced serum and liver cholesterol in rats on specific diets and inhibited cholesterol uptake.
- Tetronics 701 and 702 effectively precipitated cholesterol from micelles in vitro.
- Tetronic 701 derivatives, particularly the tetrabenzoate, showed hypocholesterolemic effects with less growth depression.
Conclusions:
- Tetronic 701 and 702 possess significant hypocholesterolemic properties.
- The mechanism involves inhibiting cholesterol uptake and potentially precipitating cholesterol.
- Tetronic 701 derivatives represent promising candidates for cholesterol-lowering therapies with improved safety profiles.
More Related Videos
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...